TopNewsOn
Health

STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment

Adam Feuerstein·STAT News·November 19, 2026

Did the biotech company Erasca find a more potent, better-tolerated pan-RAS cancer drug than Revolution Medicines?

Read the full story at STAT News →